Shares of Cipla gained nearly 3% in Wednesday’s trade after the pharmaceutical major announced its Q4FY26 results and declared a final dividend of ₹13 per share for the financial year 2025-26.
The stock was trading around ₹1,329 on the NSE, compared to its previous close of ₹1,292, even as the company reported earnings below analyst estimates.
For the quarter ended March 2026, Cipla reported a consolidated net profit of ₹554.6 crore, sharply lower than analyst estimates of ₹724 crore. The company had posted a profit of ₹1,221.8 crore in the corresponding quarter last year, marking a year-on-year decline of 54.6%.
Revenue from operations came in at ₹6,451.2 crore, down 3% YoY from ₹6,730 crore and below analyst estimates of ₹6,739 crore.
Operational performance also remained under pressure during the quarter. EBITDA stood at ₹955 crore versus analyst estimates of ₹1,034 crore. The figure declined 38% year-on-year from ₹1,537.6 crore reported in Q4FY25.
EBITDA margin contracted sharply to 14.6% from 22.8% a year ago and also came below analyst expectations of 15.3%.
However, excluding impairment charges, Cipla reported adjusted EBITDA of ₹997 crore with an adjusted EBITDA margin of 15.2%, offering some relief on the operational front.
Despite the weak year-on-year comparison and miss versus estimates, investors appeared encouraged by the company’s dividend announcement and the adjusted operating performance.
The board approved a final dividend of ₹13 per equity share for FY26.
Cipla remains one of India’s leading pharmaceutical companies with a strong presence across respiratory therapies, anti-infectives, chronic treatments and global generics markets. The company has also been focusing on strengthening its India business, complex generics pipeline and respiratory portfolio in international markets.